logo
Plus   Neg
Share
Email

Merck: European Commission Approves KEYTRUDA, Inlyta Combination To Treat RCC

Merck (MRK) said the European Commission has approved KEYTRUDA combined with Inlyta for the first-line treatment of patients with advanced renal cell carcinoma. The company noted that this is the first anti-PD-1 therapy approved as Part of a combination regimen in Europe for renal cell carcinoma across all IMDC risk groups. The approval was based on data from KEYNOTE-426 trial.

Merck said the approval allows marketing of the KEYTRUDA combination in all 28 EU member states plus Iceland, Lichtenstein and Norway.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
European Union has ordered Broadcom (AVG) to stop applying certain exclusivity agreements with six of its main customers. According to European Union, this will prevent serious and irreparable harm to competition likely to be caused by Broadcom's conduct. In June, the European Commission opened... Amazon.com Inc. (AMZN) announced that it will live stream behind the scenes of its Robotics Fulfillment Center to for students pursuing STEM and Computer Science education. Amazon said on Thursday, October 17 at 7:00 p.m. ET / 4:00 p.m. PT, teachers and students can go online to Twitch to watch and... Walmart has rolled back prices on more than 200 additional toys in stores and online as it braces for the upcoming holiday season. The retail giant is now offering more than 400 toys at a special price, thanks to its already existing rollbacks on toys. In August, Walmart unveiled its list of top-rated toys for 2019 that were selected by kids.
Follow RTT
>